Bladder Cancer Treatment Market is expected to hit USD 7.52 Bn by 2029 at a CAGR of 9.2 percent – says Maximize Market Research
May 30, 2023 08:08 ET
|
MAXIMIZE MARKET RESEARCH PRIVATE LIMITED
Pune, May 30, 2023 (GLOBE NEWSWIRE) -- A global Healthcare research and business-consulting firm, Maximize Market Research, has published a market intelligence report on the “Bladder Cancer...
Theralase® Releases FY2022 Audited Financial Statements
April 26, 2023 18:01 ET
|
Theralase Technologies Inc.
TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium
February 23, 2023 07:00 ET
|
Theralase Technologies Inc.
TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Criterium, Inc. Announces Formation of New Oncology Research Consortium for Genito-Urinary Indications
January 26, 2023 09:30 ET
|
Criterium Inc.
SARATOGA SPRINGS, N.Y., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Criterium, Inc., a full-service Contract Research Organization (CRO), is pleased to announce AURIC (Academic Urology Research Investigators...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium
January 25, 2023 07:00 ET
|
Theralase Technologies Inc.
TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase Releases Q222 Interim Financial Statements
August 29, 2022 19:45 ET
|
Theralase Technologies Inc.
TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Expands Intellectual Property Portfolio
June 28, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Research - One of the Top 10 Most Downloaded Papers
June 24, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Phase Ib NMIBC Clinical Study Published
June 21, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Releases Q122 Interim Financial Statements
May 30, 2022 17:53 ET
|
Theralase Technologies Inc.
TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...